AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14693626
Drug: Intrathecal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal ropivacaine 2.5 mg (group R)
Trial: 14693626
Drug: Intrathecal levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal levobupivacaine 2.5 mg (group L)
Trial: 9520073
Drug: New levodopa/benserazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New levodopa/benserazide formulation (Madopar DR)
Trial: 9520073
Drug: New levodopa/benserazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New levodopa/benserazide formulation (Madopar DR) after standard breakfast
Trial: 9520073
Drug: New levodopa/benserazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New levodopa/benserazide formulation (Madopar DR) in fasted condition
Trial: 9520073
Drug: New levodopa/benserazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New levodopa/benserazide formulation (Madopar DR) with food
Trial: 7737238
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tiracizine hydrochloride
Trial: 7737238
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tiracizine hydrochloride
Trial: 7737238
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tiracizine hydrochloride
Trial: 7737238
Drug: Tiracizine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiracizine (all doses)
Trial: 7737238
Drug: Tiracizine (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiracizine (serum concentrations about 80 ng/ml)
Trial: 2537562
Drug: Enalapril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril plus diuretics (n = 72)
Trial: 2537562
Drug: Digoxin plus
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin plus diuretics (n = 70)
Trial: 31748939
Drug: Pre-release methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-release methadone treatment
Trial: 26179184
Drug: Inotropic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inotropic therapy (Milrinone in 84.8% and Dobutamine in 15.2%)
Trial: 26179184
Drug: Inotropic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inotropic therapy as a bridge to transplant/LVAD
Trial: 20833488
Drug: Dietary soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary soy supplementation (90 mg of isoflavone)
Trial: 20833488
Drug: Low-dose hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose hormone therapy (1mg estradiol and 0.5mg norethisterone acetate)
Trial: 18408610
Drug: Methylphenidate (MPH;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH; Ritalin; 20 mg)
Trial: 18408610
Drug: Placebo (PLA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA; 20 mg)
Trial: 15651723
Drug: Once-daily regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily regimen of 2 mg trichlormethiazide
Trial: 15651723
Drug: Twice-daily regimen
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily regimen of 2 mg trichlormethiazide
Trial: 10891662
Drug: Suppressive doses
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppressive doses of levothyroxine for 18 months
Trial: 7503088
Drug: Suppressive doses
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppressive doses of levothyroxine
Trial: 1846783
Drug: Endothelin-1 (ET)
RxNorm normalized name: nitric oxide synthase endothelial
DrugBank: Endothelin-1 (DB12652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin-1 (ET) infusion at low dose (0.5 ng/min/100 ml forearm tissue)
Trial: 1846783
Drug: Endothelin-1 (ET)
RxNorm normalized name: nitric oxide synthase endothelial
DrugBank: Endothelin-1 (DB12652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin-1 (ET) infusion at high doses (25 and 50 ng/min/100 ml forearm tissue)
Trial: 1846783
Drug: Nifedipine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (6 micrograms/min/100 ml forearm tissue)
Trial: 1846783
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 micrograms/min/100 ml forearm tissue)
Trial: 1846783
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (0.6 micrograms/min/100 ml forearm tissue)
Trial: 1846783
Drug: Acetylcholine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine (16 micrograms/min/100 ml forearm tissue)
Trial: 6357805
Drug: Adriamycin 70
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin 70 mg/m2 i.v. on day 1 of a 3-week cycle for 8 courses, followed by CMF regimen until relapse.
Trial: 6357805
Drug: Vincristine 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine 1.4 mg/m2 i.v. on days 1 and 8 during treatment with adriamycin.
Trial: 6357805
Drug: Adriamycin 70
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin 70 mg/m2 i.v. on day 1 of a 3-week cycle for 8 courses, followed by CMF regimen until relapse (group A).
Trial: 6357805
Drug: Vincristine 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine 1.4 mg/m2 i.v. on days 1 and 8 during treatment with adriamycin (group AV).
Trial: 6357805
Drug: Adriamycin 70
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin 70 mg/m2 i.v. on day 1 of a 3-week cycle for 8 courses (group A).
Trial: 30606237
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (CHM) granules (4.9 g twice daily) plus salmeterol/fluticasone propionate combination for 12 weeks
Trial: 30606237
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo plus salmeterol/fluticasone propionate combination for 12 weeks
Trial: 26300464
Drug: Simultaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous treatment with ingenol mebutate gel (0.015% and 0.05%)
Trial: 26300464
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with ingenol mebutate gel (0.015% and 0.05%)
Trial: 7552095
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol
Trial: 16466169
Drug: Feiji Recipe
RxNorm normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feiji Recipe (FJR) and chemotherapy
Trial: 12504039
Drug: Conventional fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionation radiation therapy (Arm A)
Trial: 12504039
Drug: Conventional fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionation RT plus concomitant chemotherapy (Arm C)
Trial: 10817001
Drug: Alfentanyl (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanyl (bolus dose of 50 micrograms.kg‐1 and continuous infusion of 0.50 microgram.kg‐1.min‐1)
Trial: 10817001
Drug: Fentanyl (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (bolus dose of 5 micrograms.kg‐1 and continuous infusion of 0.16 microgram.kg‐1.min‐1)
Trial: 8776186
Drug: Heparin-coated group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated group (Group H)
Trial: 1498061
Drug: 9 intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 intravenous CMF courses (cyclophosphamide, methotrexate, 5FU) - 113 patients
Trial: 27555618
Drug: Retrograde rhinopharyngeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrograde rhinopharyngeal clearance with physiological solution (0.9%) instillation
Trial: 6502317
Drug: Fenfluramine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine 1.5 mg/kg daily (0.75 mg/kg twice daily) for 8 months
Trial: 31175425
Drug: Social counseling
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social counseling and therapy led by a social worker, six sessions of 60 min each in 3 weeks
Trial: 31175425
Drug: Social counseling
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social counseling and therapy led by a social worker
Trial: 23066769
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC) 2000 mg daily
Trial: 20509857
Drug: PIO (pioglitazone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIO (pioglitazone) 15 mg, twice a day
Trial: 20509857
Drug: GLIM (glimepiride)
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GLIM (glimepiride) 1 mg, twice a day
Trial: 11884967
Drug: biv‐WC (killed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biv‐WC (killed oral cholera vaccine)
Trial: 11884967
Drug: rBS‐WC (commercially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rBS‐WC (commercially available monovalent oral cholera vaccine)
Trial: 1695491
Drug: Plasmodium vivax
RxNorm normalized name: Plasmodium vivax Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmodium vivax sporozoite vaccine at 10 micrograms
Trial: 1695491
Drug: Plasmodium vivax
RxNorm normalized name: Plasmodium vivax Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmodium vivax sporozoite vaccine at 100 micrograms
Trial: 1695491
Drug: Plasmodium vivax
RxNorm normalized name: Plasmodium vivax Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmodium vivax sporozoite vaccine at 1,000 micrograms
Trial: 1695491
Drug: Plasmodium vivax
RxNorm normalized name: Plasmodium vivax Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmodium vivax sporozoite vaccine (all doses)
Trial: 29336859
Drug: Chemotherapy counselling
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy counselling by pharmacists based on the 'Managing Patients on Chemotherapy' module
Trial: 28510680
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron polysaccharide, 150 mg twice daily for 16 weeks
Trial: 28510680
Drug: Placebo, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 150 mg twice daily for 16 weeks
Trial: 28510680
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron polysaccharide
Trial: 26152766
Drug: Glucagon doses
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon doses studied in both groups
Trial: 21923567
Drug: Topical fusidic
RxNorm normalized name: fusidate Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fusidic acid cream
Trial: 21923567
Drug: Single-dose clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose clarithromycin
Trial: 19102912
Drug: High density
RxNorm normalized name: High density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High density lipoprotein‐cholesterol (HDL) levels > 1.04 mmol/L in ACS patients
Trial: 10824623
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's Wort extract (300 mg tablet standardized to 0.3% hypericin, taken three times a day for 14 days)
Trial: 6148842
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy of dynamic type (ST)
Trial: 6148843
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (R)
Trial: 6148843
Drug: Basal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal therapy (B)
Trial: 31466618
Drug: Biomarker-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker-guided therapy (NT-proBNP reduction to ≤1,000 pg/ml)
Trial: 27478305
Drug: Tr14 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tr14 tablets
Trial: 22510305
Drug: Exenatide QW
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide QW (once weekly)
Trial: 20119581
Drug: Triple H.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple H. pylori eradication therapy for 7 days
Trial: 14655915
Drug: Metyrapone (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (4.5 g)
Trial: 14655915
Drug: Metyrapone (6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (6.0 g)
Trial: 29843226
Drug: Hydrocortisone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (100 mg over 10 min)
Trial: 26687959
Drug: Dulanermin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulanermin (8 mg/kg)
Trial: 26687959
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2 weekly)
Trial: 16957427
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor arm
Trial: 15004821
Drug: 595 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 595 nm pulsed dye laser treatment to one eye
Trial: 9033244
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg (0.25%) bupivacaine
Trial: 9033244
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg (0.125%) bupivacaine
Trial: 30265585
Drug: Topical E6005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical E6005
Trial: 29667099
Drug: Tapering NSAIDs
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering NSAIDs and DMARDs by 50% (group 2)
Trial: 20346777
Drug: 0.18% sodium
RxNorm normalized name: Dextrose 4% and 0.18% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.18% sodium hyaluronate ophthalmic solution (Rejena, Vismed)
Trial: 10368336
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g glutamine in 330 ml glucose polymer solution
Trial: 10368336
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine alone
Trial: 10368336
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g glutamine in 330 ml placebo
Trial: 6773161
Drug: Glucose-insulin-potassium
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium
Trial: 30776898
Drug: G-CPR (resuscitation-retraining
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CPR (resuscitation-retraining programme)
Trial: 30776898
Drug: G-Stan (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Stan (standard programme)
Trial: 26946616
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) herbs for tonifying Qi and kidney, and replenishing spleen
Trial: 24784832
Drug: Low Glycemic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Glycemic Index (LGI) snack (0.4 g carbohydrate/kg body mass)
Trial: 24784832
Drug: High Glycemic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Glycemic Index (HGI) snack (0.4 g carbohydrate/kg body mass)
Trial: 20823895
Drug: 50,000 U
RxNorm normalized name: Decara 50,000 UNT Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 U oral cholecalciferol monthly (1600 U/day)
Trial: 20823895
Drug: 50,000 U
RxNorm normalized name: Decara 50,000 UNT Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 U oral cholecalciferol bimonthly (800 U/day)
Trial: 15834750
Drug: Vitek 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitek 2 system (bioMerieux, Marcy l'Etoile, France)
Trial: 12495243
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training twice per week (n = 20)
Trial: 9523803
Drug: 1.5% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% mepivacaine (45 mg)
Trial: 9523803
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine (60 mg)
Trial: 2692654
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cyclophosphamide and tamoxifen
Trial: 202425
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium oxide
Trial: 26369888
Drug: Higher tidal
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher tidal volume (20 ml kg(‐1) ideal body weight)
Trial: 26369888
Drug: Standard tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard tidal volume (10 ml kg(‐1) ideal body weight)
Trial: 25179854
Drug: Traditional center-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional center-based exercise therapy (TRAD)
Trial: 20820932
Drug: CRD-UFA (47
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRD-UFA (47 g SFA/d)
Trial: 20820932
Drug: CRD-SFA (86
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRD-SFA (86 g/d SFA)
Trial: 9098014
Drug: Ethanol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.5 g/kg)
Trial: 8546475
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of granisetron and methylprednisolone (MP: 10 mg/kg)
Trial: 2070983
Drug: New low-sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New low-sodium cleansing solution
Trial: 2070983
Drug: Standard polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard polyethylene glycol solution
Trial: 2070983
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of both solutions
Trial: 28530840
Drug: Benralizumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab (30 mg subcutaneously every 4 weeks or every 8 weeks)
Trial: 23432408
Drug: L. casei
RxNorm normalized name: L. casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. casei strain Shirota fermented milk
Trial: 21352464
Drug: Linagliptin 2.5
RxNorm normalized name: linagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 2.5 mg
Trial: 25583754
Drug: Linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 5 mg
Trial: 17727393
Drug: Talnetant 25
RxNorm normalized name: Talnetant
DrugBank: Talnetant (DB06429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talnetant 25 mg
Trial: 17727393
Drug: Talnetant 100
RxNorm normalized name: Talnetant
DrugBank: Talnetant (DB06429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talnetant 100 mg
Trial: 9680900
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate (0.05%)‐sodium fluoride (0.04%)‐strontium (100 ppm as SrCl2) rinsing solution (CXFSr)
Trial: 7844233
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (150 mg or 300 mg daily) starting from day 13 of HRT
Trial: 7844233
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin starting from day 1 of HRT
Trial: 1097194
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg chlorthalidone daily
Trial: 28697102
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g secnidazole
Trial: 28697102
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g secnidazole
Trial: 25858178
Drug: Brief treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief treatment programme (3 sessions of breathing retraining and education)
Trial: 23686891
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at effect-site concentration of 1.5 ng/mL (R1.5)
Trial: 23686891
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at effect-site concentration of 2 ng/mL (R2)
Trial: 23686891
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at effect-site concentration of 1 ng/mL (R1)